Neuropathic Pain, Peripheral Neuropathy
Conditions
Keywords
transcutaneous magnetic stimulation, axon therapy, post-traumatic peripheral neuropathic pain
Brief summary
Compare Axon Therapy using transcutaneous magnetic stimulation (tMS) against conventional medical management in treating post-traumatic peripheral neuropathic pain (PTPNP).
Detailed description
Subjects will be consented, screened, and undergo a 7-day baseline assessment to measure pain scores and assess diary compliance. Subjects who meet inclusion criteria will undergo an in-clinic baseline evaluation, receive randomization assignment, and start their respective treatments. Those randomized to the CMM plus Axon Therapy group will receive their first Axon Therapy treatment and then have a follow-up phone call after 24 hours to assess if the patient is a candidate for Axon Therapy, that is if the subject is neuropathic or nociceptive. Those that are not candidates for Axon Therapy will be monitored for 30 days for AEs and then they will exit the study as screen failures. Screen failures will not count against enrollment numbers. All subjects will return to the clinic for follow-up assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 14 days) and Day 365 (± 30 days) and if in the CMM plus Axon Therapy group will return to the clinic for Axon Therapy treatments as follows: * Month 1: 6 treatments * WEEK 1: 3 treatments (consecutive treatments are best) * WEEK 2-4: Weekly treatments * Month 2: Bi-Weekly treatment * Months 3-12: Treatments every 2-4 weeks * Additional treatments to treat flare ups; defined as an episode of pain with a VAS \>greater or equal to 6 following an increase in daily activities. At day 90 (± 15 days), subjects will be allowed to crossover to the alternative treatment group. Subjects who crossover from CMM to CMM plus Axon Therapy will follow the CMM plus Axon Therapy regimen, remaining in the study for 15 months. These subjects will have follow-up visits at Day 120 (± 14 days), Day 180 (± 14 days) ,Day 270 (± 14 days), and Day 450 (± 30 days). Subjects who crossover from CMM plus Axon Therapy to CMM will be monitored for 30 days for AEs and then they will exit the study. The reason for ending therapy will be recorded. In addition to in-clinic assessments and treatments, all subjects will complete an electronic daily diary up to twice daily throughout the first 90 days and for crossover subjects they will complete 90 days of Axon treatment therapy and up to Day 180. They will receive weekly phone follow-up to assess pain intensity and occurrence of adverse events after treatment starts. Weekly phone follow-ups will only occur during weeks when the subject is not seen in the clinic.
Interventions
DEVICECMM + Axon Therapy
transcutaneous magnetic stimulation (tMS)
Sponsors
NeuraLace Medical, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a prospective, randomized, controlled, multi-center, clinical trial in which 80 participants diagnosed with PTPNP will be randomized 1:1 into one of two treatment groups: 1. CMM plus Axon Therapy (n=64) 2. CMM alone (n=64)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Evidence of a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the study. 2. Subject is willing and able to comply with scheduled visits, treatment plan, daily pain, and other study procedures subject is able and willing to complete twice daily diary. 3. Subject must be literate in English to fill out the study questionnaires. 4. Men or women of any race or ethnicity who are 18-75 years of age. 5. Subject must have chronic peripheral neuropathic pain present for more than three months after a traumatic or surgical event per medical history (this may include, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns, or crush injury). 6. Subject has a score ≥6 on VAS at Enrollment/Screening Visit. 7. Subject has completed at least one of the two daily pain diary entries on at least three days between the Enrollment/Screening Visit and Randomization Visit (Visit 1) with a mean pain score of ≥4 and ≤10 based on Daily VAS to be eligible for randomization. 8. Subject has been on a stable pain medication regimen for at least 28 days or is not taking pain medications, as determined by the investigator, at the baseline assessment in this study. 9. Subject must have their implicated peripheral nerve(s) identified and documented in their medical record.
Exclusion criteria
1. Subjects with neuropathic pain due to post-herpetic neuropathy, HIV, trigeminal neuralgia, or carpal tunnel syndrome; subjects whose post- traumatic neuropathic pain is categorized as central (e.g., spinal cord injury) rather than peripheral. 2. Subject has a currently diagnosed progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, or severe/critical spinal stenosis (stenosis). 3. Subjects with skin conditions in the affected dermatome that in the judgment of the investigator could interfere with evaluation of the neuropathic pain condition. 4. Subjects with other pain that may confound assessment or self-evaluation of the peripheral neuropathic pain; subjects with significant somatic pain at the site of their trauma that may confound assessment or self-evaluation of their neuropathic pain. 5. Participation in any other clinical trial within the 30 days prior to screening and/or during participation in this study. 6. Any subject considered at risk of suicide or self-harm based on investigator judgment and/or the details of a risk assessment. 7. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality, or other factors that may increase the risk associated with study participation or investigational product administration or may interfere with compliance or the interpretation of study results and, in the judgment of the investigator would make the subject inappropriate to participate in the study. 8. Subjects with pending Worker's Compensation, Worker's Compensation, civil litigation, or disability claims pertinent to the subject based upon trauma; current involvement in out-of-court settlements for claims pertinent to subject's trauma; Subjects with fully resolved litigation and compensation claims can participate. 9. Subjects who have had a diagnosis of malignancy other than basal cell carcinoma, or carcinoma in situ of the cervix within the past five years, to include life expectancy less than 1 year due to advanced malignancy. 10. Subjects with implantable electrical medical devices such as a cardiac pacemaker, defibrillator, or insulin pump within four (4) inches or less of the site of pain to be treated by Axon Therapy. (Subject with an implantable device greater than four (4) inches from the site of pain to be treated should NOT be excluded). 11. Phantom limb pain or pain that feels like it is coming from a body part that is no longer there. 12. Subjects who have failed other neuromodulation implantable device for the same indication 13. Subjects with shrapnel or ferromagnetic objects 14. Subject is currently taking a morphine equivalent daily dose \> 120 mg/day. 15. Subject is a woman of childbearing potential, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the Proportion of Responders | 90 days | The primary effectiveness endpoint is a between groups comparison of the proportion of responders, defined as a subject who experiences 50% or greater reduction from baseline in neuropathic pain intensity as measured by in-clinic visual analog score (VAS) for primary area of pain at Day 90 with no increase in baseline pain medications within 4 weeks of the Day 90 visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brief Pain (BPI Inventory | 90 days | The secondary endpoints of this trial are between group comparisons |
| Daily Sleep Interference Scale (DSIS) | 30 and 90 days | The secondary endpoints of this trial are between group comparisons |
| 5D-5D-3L | 90 days | The secondary endpoints of this trial are between group comparisons |
| Patient Global Impression of Change (PGIC) | 90 days | The secondary endpoints of this trial are between group comparisons |
| Depression Anxiety Stress Scales (DASS) | 90 days | The secondary endpoints of this trial are between group comparisons b |
| Pain Disability Index (PDI) | 90 days | The secondary endpoints of this trial are between group comparisons |
| Visual Analog Scale (VAS) for Pain | 30 and 90 days | Scores from daily diaries at 30 and 90 days (analysis will include a comparison of compliance across treatment groups) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Mean/percent reduction in morphine equivalent daily dose (MEDD) | Day 180 and 365 | Based on prescribed dosages with Axon Treatment Therapy or Gabapentin equivalence for any CMM subjects |
| Proportion of subjects who discontinue treatment and/or change treatment arms | Day 90 | Proportion of subjects who discontinue treatment and/or change treatment arms |
| Proportion of subjects in each satisfaction category at Day 180 and 365 (Subjects on Axon Therapy). | Day 180 and Day 365 | Proportion of subjects in each satisfaction category at Day 180 and 365 (Subjects on Axon Therapy). |
| Improvement in PDI score | 365 Days | Proportion of subjects with clinically meaningful change as 10 point improvement, in PDI score 365 days post start of treatment as compared to baseline, subjects on a Axon Therapy |
| Reduction or elimination non-opioid pain medications | 365 Days | Subjects on Axon Therapy and based on prescribed dosages |
Countries
United States
Outcome results
None listed